XNAS · Healthcare · Biotechnology
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-14 | Q2 2026 | -0.15 | -0.14 | +6.67% | $0 | ✅ Beat | -2.17% | -19.03% | — |
| 2026-05-15 | Q1 2026 | -0.11 | -0.13 | -18.18% | $0 | ❌ Miss | +2.60% | +8.23% | -1.73% |
| 2026-04-01 |
| Q4 2025 |
| -0.13 |
| -0.13 |
| +0.00% |
| $0 |
| ➖ Inline |
| +1.68% |
| +11.73% |
| +43.83% |
| 2025-11-14 | Q3 2025 | -0.15 | -0.14 | +6.67% | $0 | ✅ Beat | — | — | — |
| 2024-11-14 | Q4 2024 | — | -1.37 | — | $0 | — | -4.08% | -31.63% | -15.51% |
Showing last 5 quarters.